NRSN logo

NeuroSense Therapeutics Ltd.

NRSN
Healthcare|Biotechnology|IL
$1.68
+0.28 (+20.43%)
Cash / Share
$0.18

About

NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical development phase, committed to discovering and developing effective therapies for individuals suffering from severe neurodegenerative conditions. The company's leading drug candidate, PrimeC, is an innovative oral formulation that has successfully concluded Phase IIa clinical investigations for the management of amyotrophic lateral sclerosis (ALS). Additionally, its early-stage research pipeline features StabiliC, a potential treatment for Parkinson's disease, and CogniC, which is under development for Alzheimer's disease. Established in 2017, NeuroSense Therapeutics Ltd. is headquartered in Herzliya, Israel.

Stock Price

-91.8%(1Y)
1M
-53.1%
3M
-83.2%
6M
-90.5%
YTD
-89.1%
1Y
-91.1%
3Y
-84.4%
5Y
-97.9%

Pipeline Summary

6 total trials
3
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
Completed: 5Terminated: 1

Key Facts

Market Cap$3.2M
Employees16
CEOAlon Ben-Noon
IPO DateDec 9, 2021
Beta1.72
52-Week Range$1.1 – $25.4
Avg Volume25,781
ExchangeNASDAQ
Websiteneurosense-tx.com

Ownership

Float62.9%
Shares Outstanding1.9M

Recent Insider Trades

Ben-Noon AlonBUY
Jun 16, 2026250,000 shares @ $0.80
Eisenberg OrBUY
Jun 16, 2026250,000 shares @ $0.80
Eisenberg OrAWARD
Mar 26, 2026200,000 shares
Eisenberg OrOTHER
Mar 18, 20260 shares
Eisenberg OrOTHER
Mar 18, 20260 shares

Peers

CLGNCollPlant Biotechnologies Ltd.
$7.5M
CVKDCadrenal Therapeutics, Inc. Common Stock
$3.5M
ENLVEnlivex Therapeutics Ltd.
$21.4M
KLTOKlotho Neurosciences, Inc.
$20.1M
NERVMinerva Neurosciences, Inc.
$115.5M
NRXSNeurAxis, Inc.
$78.4M
RLYBRallybio Corporation
$84.8M
SONNSonnet BioTherapeutics Holdings, Inc.
$8.4M

Recent News

NeuroSense to Strengthen PrimeC Canadian ALS Submission With New NfL Data
Nov 2, 2026 · prnewswire.com
NeuroSense to Present Integrated Clinical and Biomarker Evidence Shaping PrimeC's Phase 3 Development at NEALS 2026
Oct 29, 2026 · prnewswire.com
NeuroSense Files U.S. Patent Application for Traumatic Brain Injury
Oct 19, 2026 · prnewswire.com
NeuroSense Secures Nasdaq Hearing Date as PrimeC Approaches Key Regulatory and Funding Milestones
Oct 13, 2026 · prnewswire.com
NeuroSense Provides Update on Nasdaq Listing Compliance
Oct 2, 2026 · prnewswire.com
Data last updated: Nov 9, 2026, 04:24 AM